Wang X, Li J, Qin R, Yin Y, Li J, Lin S
Front Mol Biosci. 2025; 12:1523494.
PMID: 40070686
PMC: 11893430.
DOI: 10.3389/fmolb.2025.1523494.
Zhao Y, Song Y, Li W, Wu J, Zhao Z, Qu T
Cancer Immunol Immunother. 2025; 74(4):137.
PMID: 40053076
PMC: 11889303.
DOI: 10.1007/s00262-025-03994-5.
Du X, Luo W, Li H, Gu Q, Huang P, Wang C
Mol Cancer. 2025; 24(1):59.
PMID: 40011917
PMC: 11866803.
DOI: 10.1186/s12943-025-02259-0.
Zhong Y, Wang Y, Wang C, Cao K, Wang X, Xu X
J Immunother Cancer. 2025; 13(2).
PMID: 40010770
PMC: 11873354.
DOI: 10.1136/jitc-2024-011230.
Wang S, Xie D, Yue H, Li G, Jiang B, Gao Y
Biomedicines. 2025; 13(2).
PMID: 40002717
PMC: 11853330.
DOI: 10.3390/biomedicines13020304.
L. Extract Inhibits Colorectal Cancer Tumor Growth by Modulating Cell Apoptosis and Autophagy.
Tsai M, Chen C, Chen C, Lee M, Wu L, Hsu Y
Curr Issues Mol Biol. 2025; 47(2).
PMID: 39996849
PMC: 11854706.
DOI: 10.3390/cimb47020128.
Long noncoding RNA mediates enzalutamide resistance and transformation in neuroendocrine prostate cancer.
Zhu Z, Xuan W, Wang C, Li C
Front Oncol. 2024; 14:1481777.
PMID: 39655078
PMC: 11625809.
DOI: 10.3389/fonc.2024.1481777.
A novel micropeptide miPEP205 suppresses the growth and metastasis of TNBC.
Zhang Z, Li F, Dai X, Deng J, Wang Y, Zhang S
Oncogene. 2024; 44(8):513-529.
PMID: 39623077
DOI: 10.1038/s41388-024-03240-9.
A phase I dose-escalation study of LRP5/6 antagonist BI 905677 in patients with advanced solid tumors.
Lenz H, Argiles G, de Jonge M, Yaeger R, Doi T, El-Khoueiry A
ESMO Open. 2024; 9(11):103729.
PMID: 39617530
PMC: 11670700.
DOI: 10.1016/j.esmoop.2024.103729.
Amygdalin inhibits endometrial stromal cell proliferation, migration, and invasion in endometriosis mice via inhibiting Wnt/β-catenin signaling.
Yu M, Yang L, Pei Y, Xu M
J Mol Histol. 2024; 56(1):11.
PMID: 39612044
DOI: 10.1007/s10735-024-10301-6.
Erianin inhibits the progression of DDP-resistant lung adenocarcinoma by regulating the Wnt/β-catenin pathway and activating the caspase-3 for apoptosis in vitro and in vivo.
Tang L, Ruan Y, Wang B, Zhang M, Xue J, Wang T
Hereditas. 2024; 161(1):48.
PMID: 39605083
PMC: 11600767.
DOI: 10.1186/s41065-024-00351-x.
Chemical approaches targeting the hurdles of hepatocyte transplantation: mechanisms, applications, and advances.
Shi H, Ding Y, Sun P, Lv Z, Wang C, Ma H
Front Cell Dev Biol. 2024; 12:1480226.
PMID: 39544361
PMC: 11560891.
DOI: 10.3389/fcell.2024.1480226.
Oxidative Stress, Glutaredoxins, and Their Therapeutic Potential in Posterior Capsular Opacification.
Li C, Yan W, Yan H
Antioxidants (Basel). 2024; 13(10).
PMID: 39456463
PMC: 11504336.
DOI: 10.3390/antiox13101210.
RNA modification in normal hematopoiesis and hematologic malignancies.
Chen X, Yuan Y, Zhou F, Li L, Pu J, Jiang X
MedComm (2020). 2024; 5(11):e787.
PMID: 39445003
PMC: 11496571.
DOI: 10.1002/mco2.787.
Regulation of mA (N-Methyladenosine) methylation modifiers in solid cancers.
Singh S, Gupta S, Abhishek R, Sachan M
Funct Integr Genomics. 2024; 24(6):193.
PMID: 39438339
DOI: 10.1007/s10142-024-01467-z.
Deciphering the impact of TERT/telomerase on immunosenescence and T cell revitalization.
Huang L, Zhang M, Bai D, Qu Y
Front Immunol. 2024; 15:1465006.
PMID: 39376566
PMC: 11456497.
DOI: 10.3389/fimmu.2024.1465006.
Novel biomarkers and drug correlations of non-canonical WNT signaling in prostate and breast cancer.
Huang Y, Fan M, Liu Y, Jiang X, Du K, Wu A
Discov Oncol. 2024; 15(1):511.
PMID: 39347881
PMC: 11442966.
DOI: 10.1007/s12672-024-01394-2.
RNA m6A modification in ferroptosis: implications for advancing tumor immunotherapy.
Shi J, Zhang Z, Yin H, Piao X, Liu C, Liu Q
Mol Cancer. 2024; 23(1):213.
PMID: 39342168
PMC: 11437708.
DOI: 10.1186/s12943-024-02132-6.
Integrated Identification and Immunotherapy Response Analysis of the Prognostic Signature Associated With m6A, Cuproptosis-Related, Ferroptosis-Related lncRNA in Endometrial Cancer.
Qian Y, Chen H, Miao P, Ma R, Lu B, Hu C
Cancer Rep (Hoboken). 2024; 7(9):e70009.
PMID: 39324703
PMC: 11425647.
DOI: 10.1002/cnr2.70009.
LINC01094: A key long non-coding RNA in the regulation of cancer progression and therapeutic targets.
Yi Q, Zhu G, Zhu W, Wang J, Ouyang X, Yang K
Heliyon. 2024; 10(18):e37527.
PMID: 39309878
PMC: 11415682.
DOI: 10.1016/j.heliyon.2024.e37527.